



CENTER FOR CANCER IMMUNTERAPI HÆMATOLOGISK AFDELING PAVILLON 9 6509 KØBENHAVNS UNIVERSITETSHOSPITAL · HERLEV HERLEV RINGVEJ 75 2730 HERLEV

T +45 3868 9339 F +45 3868 4153

HEH-CCIT@REGIONH.DK WWW.HERLEVHOSPITAL.DK/CCIT-DENMARK

Engineering T cells against cancer vulnerabilities

Sebastian Kobold, M.D., PhD Division of Clinical Pharmacology, Department of Medicine IV Klinikum der Universität München München - Germany Sebastian.kobold@med.uni-muenchen.de

Center for Cancer Immune Therapy Seminar – 2025, March 11th, at 14.00, in meeting room C (in J2) – all are welcome.

Abstract

Cellular therapies part of the standard of care in many hematological malignancies, where they can cure even advanced stages of refractory disease. For a long time, solid oncology was a blank spot to cellular therapeutics, but the past year have seen two approvals in the US, indicating that under certain circumstances and in distinct disease situations cellular therapeutics may deliver benefit to solid cancer patients. Conventional development is a top down approach, driven by empirical hypothesis generation, relying mostly on expression of a given target or structure. While this approach has proven successful in the past years, progress is slow, and the question emerges if more effective ways of therapeutic design and hypothesis testing exist. In my talk I will discuss the possibility of leveraging disease driving or key disease pathways related to immunity to design bettered cellular therapeutics. I will describe specific published and unpublished examples how such strategy could be used to identify actionable candidate for cancer cell targeting, recruitment and immune suppression.

